Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.78 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8115506 | 0.91 | SLC2A1 (0.73) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL24496704 | 0.90 | SLC2A1 (0.72) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL21174962 | 0.90 | MAOB (0.70) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL8107014 | 0.90 | KDM4E (0.76) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL5322779 | 0.90 | KDM4E (0.76) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL10459171 | 0.89 | SLC2A1 (0.71) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL10690984 | 0.87 | AKR1B1 (0.69) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 | |
| SCHEMBL426292 | 0.86 | KDM4E (0.72) | SLC2A1AKR1B1KDM4EALDH1A1GAA | |
| SCHEMBL8115968 | 0.86 | SLC2A1 (0.60) | SLC2A1AKR1B1KDM4EALDH1A1GAA | |
| SCHEMBL6331153 | 0.86 | AKR1B1 (0.67) | SLC2A1AKR1B1KDM4EMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2450346-A1 | Antagonists of the TRPV1 receptor and uses thereof | Abbott Laboratories (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| EP-0634409-B1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL CO (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0986552-A1 | 5-NAPHTHALEN-1-YL-1,3-DIOXANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998055474-A1 | 5-NAPHTHALEN-1-YL-1,3-DIOXANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1998-12-10 | — | — | WO | disclosed |
| US-5659051-A | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0634409-A1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC2A1 2856/4885AKR1B1 750/4885KDM4E 4626/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC2A1 2968/4885AKR1B1 846/4885KDM4E 4625/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC2A1 2856/4885AKR1B1 750/4885KDM4E 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.